{
  "id": 12040058,
  "title": "CSL to pay up to $1.6 bln to develop rare disease drug; shares rise",
  "url": "https://urgent.news/2026/10/05/csl-to-pay-up-to-1-6-bln-to-develop-rare-disease-drug-shares-rise",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-05T00:53:05.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/csl-to-pay-up-to-16-bln-to-develop-rare-disease-drug-shares-rise-4930976"
  },
  "original_language": "en",
  "account": "On Monday, CSL Ltd (ASX:CSL) shares increased as the Australian healthcare firm revealed it had agreed to spend up to $1.6 billion to jointly create and bring to market a novel treatment for rare kidney and liver ailments. The company disclosed that it would initially transfer $355 million to Alentis Therapeutics, with the Swiss biotech firm entitled to a maximum of $1.2 billion in milestone payments contingent on the commercial success of the therapy. CSL's shares on the Sydney Stock Exchange climbed 1.1% to A$177.20 by 00:47 GMT.\n\nIn addition to the financial commitment, CSL will support the ongoing and planned clinical trials of lixudebart, an experimental drug currently being evaluated in individuals with ANCA-associated vasculitis and rapidly progressive glomerulonephritis. These rare autoimmune disorders can lead to severe and permanent kidney impairment. The entities also intend to develop the medication for focal segmental glomerulosclerosis, a persistent kidney disorder, and primary sclerosing cholangitis, a liver condition without any presently available treatment. Profits arising from global commercialization of the drug will be divided 55% to CSL and 45% to Alentis.",
  "summary": null,
  "key_points": [
    "CSL to invest up to $1.6 billion in joint rare disease drug development",
    "$355 million initial transfer to Alentis Therapeutics with $1.2 billion in milestones",
    "Shares rise 1.1% to A$177.20 on Sydney Stock Exchange"
  ],
  "editors_take": "CSL's deal with Alentis Therapeutics shifts the Australian firm's focus towards rare disease treatments, potentially boosting its portfolio and profits through a 55% share of global commercialization revenue.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}